Skip to main content

Table 1 Demographic and baseline characteristics

From: A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Parameter Placebo
(n = 21)
Volixibat
5 mg b.i.d.
(n = 9)
10 mg = q.d.
(n = 9)
20 mg q.d.
(n = 9)
2–5–10–20 mg q.d.
(n = 9)
30 mg q.d.
(n = 9)
40 mg q.d.
(n = 9)
80–40–20 mg q.d.
(n = 9)
Total
(n = 63)
Age, years 41.5
(9.47)
37.1
(15.40)
46.2
(7.61)
33.3
(9.82)
46.2
(7.82)
44.6
(10.70)
36.6
(8.92)
33.2
(11.34)
39.6
(11.41)
Men, n (%) 18
(85.7)
9
(100)
7
(77.8)
9
(100)
9
(100)
8
(88.9)
9
(100)
9
(100)
60
(95.2)
BMI, kg/m2 29.65
(1.426)
27.81
(1.614)
29.53
(2.087)
29.49
(2.587)
29.67
(3.399)
30.96
(1.368)
28.91
(1.898)
29.27
(2.971)
29.38
(2.422)
Race, n (%)
 White 8
(38.1)
4
(44.4)
4
(44.4)
4
(44.4)
7
(77.8)
3
(33.3)
9
(100)
4
(44.4)
35
(55.6)
 Black or African American 12
(57.1)
5
(55.6)
5
(55.6)
5
(55.6)
2
(22.2)
6
(66.7)
0 5
(55.6)
28
(44.4)
 American Indian or Alaska native 1
(4.8)
0 0 0 0 0 0 0 0
  1. Values are mean (standard deviation) unless otherwise stated. Data are from the safety analysis set
  2. b.i.d., twice daily; BMI, body mass index; q.d., once daily